02618nam a22005171i 4500 000710020 CaToSAGE 20240202172917.0 20180103162434.3 m|||||o||d|||||||| cr ||||||||||| 180103r20172017enk fo 000 0|eng|d NEZPRACOVANÝ IMPORT 9781526429773 (ebook) : No price (OCoLC)44258641 CaToSAGE eng CaToSAGE rda pn UtOrBLW f sa QR189.5.A33 R67 2017 615.372 23 Rosenthal, Jean, active 2017, author. Zerit / Jean Rosenthal, Ian Shapiro, Jaan Elias. London : Yale School of Management, 2017. 1 online resource. text txt rdacontent computer c rdamedia online resource cr rdacarrier SAGE Knowledge. Cases Originally published in Shapiro, I., & Elias, J. (2017). Zerit. 17-011. New Haven, CT: Yale School of Management, Yale University. Retrieved from: https://vol11.cases.som.yale.edu/zerit. In 2001, Jon Soderstrom, Director of Yale's Office of Cooperative Research, found himself in the midst of a maelstrom of negative publicity. Yale's patent on the drug Zerit had become the target of international activists and campus protests. Protestors asserted that the patent and Yale's licensing of the pharmaceutical to Bristol-Myers Squibb (BMS) was preventing low-cost generics from reaching millions suffering from HIV/AIDS in South Africa. After a meeting between Soderstrom and BMS, BMS lowered the price of Zerit in South Africa and other developing countries and the crisis cooled. But student protestors and others continued to question university policy on the use of patents in the development of new pharmaceuticals, the close relationship between big pharma and universities, and the ethics and goals of university research. Description based on XML content. elektronické knihy fd186907 czenas electronic books eczenas Soderstrom, Jon. Yale University. Office of Cooperative Research. Bristol-Myers Squibb Company. AIDS vaccines South Africa. Zerit. Shapiro, Ian, author. Elias, Jaan, author. SAGE Knowledge. Cases. SAGE Knowledge https://sk.sagepub.com/cases/zerit Plný text SBC EB NEPOSILAT EB